Press Releases

Epic Sciences Selected to Present at Cavendish Global Health Impact Forum

SAN DIEGO, May 5, 2014 /PRNewswire/ -- Epic Sciences, developer of novel diagnostics to personalize and advance the treatment and management of cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking…

Epic Sciences Appoints Pascal Bamford, Ph.D. as Vice President of Product Development

Epic Sciences announced today the appointment of Pascal Bamford, Ph.D. as vice president of product development. Dr. Bamford has more than 15 years of experience in developing complex, automated diagnostic systems for digital pathology. Prior to joining…

Epic Sciences Partners with LabCorp to Accelerate European Clinical Sample Processing CTC Technology

SAN DIEGO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support…

Epic Sciences and Collaborators to Present Six Novel Abstracts at ASCO GU Addressing the Clinical Applicability of Epic’s CTC Technology in Prostate Cancer

SAN DIEGO and SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical…

Epic Sciences Appoints Michael Rodriguez as Chief Financial Officer

SAN DIEGO, Jan. 21, 2014 /PRNewswire/ -- Epic Sciences announced today the appointment of Michael Rodriguez as chief financial officer. Mr. Rodriguez has more than 20 years of experience as a strategic financial and operational executive guiding creative…

Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO

SAN DIEGO - August 22, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the appointment of Murali K. Prahalad, Ph.D. as president and CEO. Dr. Prahalad was formerly vice president…

Epic Sciences' Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium

SAN DIEGO and ORLANDO, FLA. - February 12, 2013 -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking…

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

Epic Sciences, Inc., ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI)…

Epic Sciences Announces Series B Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced today that it has completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture…

Epic Sciences Announces Six Pharma Circulating Tumor Cell Collaborations

San Diego, CA - August 15, 2012 -- Epic Sciences, Inc. ("Epic"), a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic's proprietary Circulating Tumor Cell…